Literature DB >> 3567081

Effect of human recombinant erythropoietin on human marrow megakaryocyte colony formation in vitro.

E N Dessypris, J H Gleaton, O L Armstrong.   

Abstract

The effect of human recombinant erythropoietin (EP) on the growth of human marrow megakaryocyte colony forming units (CFU-M) in vitro was investigated by the use of a plasma clot assay. EP as a single stimulating factor or as an additional factor to optimal concentration of leucocyte conditioned medium (PHA-LCM) had no effect on the number of CFU-M derived colonies. However, addition of EP (0.5-1 U/ml) to cultures with suboptimal concentrations of PHA-LCM increased megakaryocytic colony formation by 50-90% but had no effect on the number of granulocytic-monocytic colonies (CFU-GM). Exposure of marrow cells to EP for 24-48 h in liquid suspension cultures, followed by removal of the hormone and assaying the cells for CFU-M in plasma clots, resulted in a 50-100% increase of megakaryocyte colony formation in vitro. The augmenting effect of EP on CFU-M growth in vitro was abolished when EP was added to the medium after the third day of culture. The presence of factors in human serum and in PHA-LCM was an absolute requirement for the hormone to exert its potentiating effect on human CFU-M growth in vitro. Recombinant EP potentiates the growth of human marrow CFU-M and this effect seems to be exerted during the early stages of CFU-M development in vitro.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3567081     DOI: 10.1111/j.1365-2141.1987.tb06852.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  9 in total

1.  Effect of human recombinant erythropoietin on human hemopoietic progenitor cells in vitro.

Authors:  A Ganser; B Völkers; P Scigalla; D Hoelzer
Journal:  Klin Wochenschr       Date:  1988-03-15

2.  [The effect of erythropoietin (rh-EPO) om in vitro proliferation of granulocyte/monocyte-determined stem cells in bone marrow and peripheral blood].

Authors:  U Neumann; C Kunert; H Sperschneider
Journal:  Med Klin (Munich)       Date:  1999-03-15

Review 3.  Clinical use of rHuEPO in bone marrow transplantation.

Authors:  S Klaesson
Journal:  Med Oncol       Date:  1999-04       Impact factor: 3.064

4.  Anemia and thrombocytosis induced by ribavirin monotherapy in patients with chronic hepatitis C.

Authors:  Tomoe Kobayashi; Shuhei Hige; Katsumi Terashita; Masato Nakai; Hiromasa Horimoto; Takuya Sho; Mitsuru Nakanishi; Koji Ogawa; Makoto Chuma; Naoya Sakamoto; Masahiro Asaka
Journal:  J Gastroenterol       Date:  2012-03-30       Impact factor: 7.527

5.  A multicenter randomized, double-blind, placebo-controlled late-phase II/III study of recombinant human interleukin 11 in acute myelogenous leukemia.

Authors:  Kensuke Usuki; Akio Urabe; Yasuo Ikeda; Yasuo Ohashi; Hideaki Mizoguchi; Fumimaro Takaku
Journal:  Int J Hematol       Date:  2007-01       Impact factor: 2.490

Review 6.  Erythropoietin: a review.

Authors:  D M Ridley; F Dawkins; E Perlin
Journal:  J Natl Med Assoc       Date:  1994-02       Impact factor: 1.798

7.  Recombinant human erythropoietin for the treatment of anemia in the myelodysplastic syndromes: a clinical and erythrokinetic assessment.

Authors:  G E Verhoef; P Zachée; A Ferrant; H Demuynck; D Selleslag; L Van Hove; F Deckers; M A Boogaerts
Journal:  Ann Hematol       Date:  1992-01       Impact factor: 3.673

Review 8.  Epoetin (recombinant human erythropoietin). A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in anaemia and the stimulation of erythropoiesis.

Authors:  D Faulds; E M Sorkin
Journal:  Drugs       Date:  1989-12       Impact factor: 9.546

9.  Thrombopoietin rescues in vitro erythroid colony formation from mouse embryos lacking the erythropoietin receptor.

Authors:  M W Kieran; A C Perkins; S H Orkin; L I Zon
Journal:  Proc Natl Acad Sci U S A       Date:  1996-08-20       Impact factor: 11.205

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.